We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
Read MoreHide Full Article
Inogen, Inc. (INGN - Free Report) is currently one of the top performing stocks in the MedTech space. Solid second-quarter results and a raised guidance are currently favoring the stock.
Shares Up
In the past year, shares of Inogen have skyrocketed 167.9% against the industry’s decline of 3.7%.
This Zacks Rank #2 (Buy) stock currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks, with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2, are better picks than most.
For the current quarter, the Zacks Consensus Estimate for earnings per share is pegged at 51 cents, reflecting growth of 54.6%.
Let’s delve deeper.
Factors That Make It an Attractive Pick
Solid Q2 Results
Inogen recently reported strong second-quarter results, where both earnings per share and revenues beat the consensus mark. Sales revenues totaled $92 million, up 58.5% on a year-over-year basis.
Business-to-business sales in the United States totaled $32.9 million, up 55.7% on a year-over-year basis.
Additionally, direct-to-consumer revenues in the United States grossed $38.3 million in the reported quarter. This reflects an increase of 74.3% from the prior-year quarter.
Gross margin was 49.8%, which expanded 60 basis points (bps) in the quarter under review. Operating margin was 14.4%, up 110 bps.
Inogen raised its 2018 revenue guidance to $340-$350 million from $310-$320 million, representing year-over-year growth of 36.3% to 40.3%. The Zacks Consensus Estimate is pegged at $348.8 million, within the guided range.
Inogen expects direct-to-consumer sales to be its fastest-growing channel and domestic business-to-business sales to have significant growth rate in 2018.
Internationally, business-to-business sales are expected to register solid growth too as Inogen continues to focus on European markets. However, rental revenues are expected to decline 10% in 2018. The company’s 2018 adjusted net income guidance is at $45-$48 million, up from $38-$41 million, representing year-over-year growth of 114.3% to 128.5%.
Adjusted EBITDA for the year is expected between $65 million and $69 million, up from $62-$67 million, representing 27.9% to 35.7% year-over-year growth.
Global Prospects Bright
Inogen has confirmed that its outlook for European sales in 2018 remains optimistic.
In the second quarter of 2018, sales in Europe represented 88.3% of international sales, up from 87.6% in the year-ago quarter. Inogen’s European partners significantly contributed to the company’s business-to-business sales in the reported quarter.
Key Picks
Some other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock carries a Zacks Rank #2.
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Here's Why You Should Buy Inogen (INGN) Stock Right Now
Inogen, Inc. (INGN - Free Report) is currently one of the top performing stocks in the MedTech space. Solid second-quarter results and a raised guidance are currently favoring the stock.
Shares Up
In the past year, shares of Inogen have skyrocketed 167.9% against the industry’s decline of 3.7%.
This Zacks Rank #2 (Buy) stock currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks, with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2, are better picks than most.
For the current quarter, the Zacks Consensus Estimate for earnings per share is pegged at 51 cents, reflecting growth of 54.6%.
Let’s delve deeper.
Factors That Make It an Attractive Pick
Solid Q2 Results
Inogen recently reported strong second-quarter results, where both earnings per share and revenues beat the consensus mark. Sales revenues totaled $92 million, up 58.5% on a year-over-year basis.
Business-to-business sales in the United States totaled $32.9 million, up 55.7% on a year-over-year basis.
Additionally, direct-to-consumer revenues in the United States grossed $38.3 million in the reported quarter. This reflects an increase of 74.3% from the prior-year quarter.
Gross margin was 49.8%, which expanded 60 basis points (bps) in the quarter under review. Operating margin was 14.4%, up 110 bps.
Inogen, Inc Price and Consensus
Inogen, Inc Price and Consensus | Inogen, Inc Quote
Raised Guidance
Inogen raised its 2018 revenue guidance to $340-$350 million from $310-$320 million, representing year-over-year growth of 36.3% to 40.3%. The Zacks Consensus Estimate is pegged at $348.8 million, within the guided range.
Inogen expects direct-to-consumer sales to be its fastest-growing channel and domestic business-to-business sales to have significant growth rate in 2018.
Internationally, business-to-business sales are expected to register solid growth too as Inogen continues to focus on European markets. However, rental revenues are expected to decline 10% in 2018. The company’s 2018 adjusted net income guidance is at $45-$48 million, up from $38-$41 million, representing year-over-year growth of 114.3% to 128.5%.
Adjusted EBITDA for the year is expected between $65 million and $69 million, up from $62-$67 million, representing 27.9% to 35.7% year-over-year growth.
Global Prospects Bright
Inogen has confirmed that its outlook for European sales in 2018 remains optimistic.
In the second quarter of 2018, sales in Europe represented 88.3% of international sales, up from 87.6% in the year-ago quarter. Inogen’s European partners significantly contributed to the company’s business-to-business sales in the reported quarter.
Key Picks
Some other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock carries a Zacks Rank #2.
Integer Holdings has an expected growth rate of 12.6% for the next year. The stock flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>